Video

KEYNOTE-407 Study of Frontline Pembrolizumab and Chemotherapy in Advanced NSCLC

Author(s):

Solange Peters, MD, PhDMelissa Johnson, MD

Dr Velcheti reviews data on the chemoimmunotherapy treatment of squamous NSCLC from the KEYNOTE-407 study.

Related Videos
Suresh S. Ramalingam, MD, FACP, FASCO, professor, Department of Hematology and Medical Oncology, Roberto C. Goizueta Distinguished Chair for Cancer Research, Emory University School of Medicine, executive director, Winship Cancer Institute of Emory University, associate vice president, cancer, Woodruff Health Sciences Center
Byoung Chol Cho, MD, PhD, professor, internal medicine, Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine
Ben Levy, MD, and Yan Leyfman, MD
BDTX-1535 – A MasterKey EGFR Inhibitor Targeting Classical, Non-Classical, and the C797S Resistance Mutation To Address The Evolved Landscape Of EGFR Mutant NSCLC
Video 14 - "Key Takeaways in HER2-Mutated NSCLC"
Video 13 - "Treatment Considerations in HER2-Mutated NSCLC"
Zofia Piotrowska, MD, MHS, and Martin Dietrich, MD, PhD, experts on lung cancer
Zofia Piotrowska, MD, MHS, and Martin Dietrich, MD, PhD, experts on lung cancer
A panel of 5 experts on lung cancer
A panel of 5 experts on lung cancer
Related Content
Taletrectinib in ROS1-positive non–small cell lung cancer: © stock.adobe.com
June 2nd 2024

Taletrectinib Yields Durable Responses in TKI Naive and Crizotinib Pretreated ROS1+ NSCLC

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

David R. Spigel, MD, of Sarah Cannon Research Institute
June 2nd 2024

Consolidation Durvalumab to Become New SOC for LS-SCLC After Chemoradiation

Hari B. Keshava, MD
October 23rd 2023

Keshava Emphasizes the Importance of Lung Nodule Programs for Early Lung Cancer Detection

Tony S. K. Mok, MD
June 1st 2024

Adagrasib Improves Survival, Responses in KRAS G12C+ Advanced NSCLC

Natasha B. Leighl, BSc, MMSc, MD
June 1st 2024

Subcutaneous Amivantamab Shows Noninferior ORR vs IV Formulation in EGFR+ NSCLC